×
About 2,723 results

ALLMedicine™ Systemic Mastocytosis Center

Research & Reviews  1,077 results

Cytogenetic and molecular aberrations and worse outcome for male patients in systemic m...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7681091
Theranostics Kluin-Nelemans HC, Jawhar M et. al.

Jan 4th, 2021 - In systemic mastocytosis (SM), the clinical features and survival vary greatly. Patient-related factors determining the outcome in SM are largely unknown. Methods: We examined the impact of sex on the clinical features, progression-free survival (...

A case report on concurrent occurrence of systemic mastocytosis and myeloid sarcoma pre...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7738061
Medicine Wang X, Zhang L et. al.

Dec 17th, 2020 - Systemic mastocytosis is a rare disease due to mast cell accumulation in various extracutaneous sites. Systemic mastocytosis with an associated clonal hematologic non-MC lineage disease is the second most common subtype of systemic mastocytosis. T...

Mastocytosis.
https://doi.org/10.1093/ajcp/aqaa183
American Journal of Clinical Pathology; Tzankov A, Duncavage E et. al.

Dec 14th, 2020 - The 2019 Workshop of the Society for Hematopathology/European Association for Haematopathology received and reviewed cases covering the spectrum of mastocytosis and related diseases, including morphologic mimics, focusing on recent updates and rel...

An aggressive systemic mastocytosis preceded by ovarian dysgerminoma.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7693501
BMC Cancer; Tsutsumi M, Miura H et. al.

Nov 28th, 2020 - Aggressive systemic mastocytosis (ASM) is a rare malignant disease characterized by disordered mast cell accumulation in various organs. We here describe a female ASM patient with a previous history of ovarian dysgerminoma. Molecular cytogenomic a...

Catching the clinical and biological diversity for an appropriate therapeutic approach ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7646220
Annals of Hematology; Mannelli F

Nov 6th, 2020 - Systemic mastocytosis (SM) is a rare disease calling for integrated approaches involving onco-hematologic competences for appropriate clinical management and treatment. The wide variability of manifestations and disease course claims for an accura...

see more →

Guidelines  2 results

Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2018.0088
Journal of the National Comprehensive Cancer Network : JNCCN; Gotlib J, Gerds AT et. al.

Dec 13th, 2018 - Mastocytosis is a group of heterogeneous disorders resulting from the clonal proliferation of abnormal mast cells and their accumulation in the skin and/or in various extracutaneous organs. Systemic mastocytosis is the most common form of mastocyt...

Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
http://www.jnccn.org/content/16/12/1500.full
Gotlib, J.

Nov 30th, 2018 - Mastocytosis is a group of heterogeneous disorders resulting from the clonal proliferation of abnormal mast cells and their accumulation in the skin and/or in various extracutaneous organs. Systemic mastocytosis is the most common form of mastocyt.

see more →

Drugs  251 results see all →

Clinicaltrials.gov  1,357 results

Ranitidine - ranitidine tablet, film coated-Quality Care Products, LLC
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a1d55e87-41f7-4556-95af-0854c1b1c1bd

Jan 10th, 2021 - Ranitidine tablets USP are indicated in: 1.Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more t...

Cytogenetic and molecular aberrations and worse outcome for male patients in systemic m...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7681091
Theranostics Kluin-Nelemans HC, Jawhar M et. al.

Jan 4th, 2021 - In systemic mastocytosis (SM), the clinical features and survival vary greatly. Patient-related factors determining the outcome in SM are largely unknown. Methods: We examined the impact of sex on the clinical features, progression-free survival (...

Ranitidine - ranitidine solution-Amneal Pharmaceuticals LLC
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8f0bb213-6342-4fea-a080-24def590d1ba

Dec 28th, 2020 - Ranitidine Oral Solution is indicated in: Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more th...

Ranitidine - ranitidine tablet-Amneal Pharmaceuticals LLC
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9f416ce0-012f-4194-9382-74ac71e4b2a9

Dec 28th, 2020 - Ranitidine Tablets are indicated in: 1. Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than...

A case report on concurrent occurrence of systemic mastocytosis and myeloid sarcoma pre...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7738061
Medicine Wang X, Zhang L et. al.

Dec 17th, 2020 - Systemic mastocytosis is a rare disease due to mast cell accumulation in various extracutaneous sites. Systemic mastocytosis with an associated clonal hematologic non-MC lineage disease is the second most common subtype of systemic mastocytosis. T...

see more →

News  31 results

Gene-targeting therapy shown to reduce mastocytosis symptoms
https://www.mdedge.com/familymedicine/article/219888/asthma/gene-targeting-therapy-shown-reduce-mastocytosis-symptoms?channel=39313
CHEST Physician; Richard Mark Kirkner

Mar 31st, 2020 - A small-molecule kinase inhibitor that targets a gene mutation complicit in systemic mastocytosis has been found to reduce symptoms by about 30%, according to early results of a clinical trial scheduled to be presented at the American Academy of A.

Inhibitor can improve symptoms of systemic mastocytosis
https://www.mdedge.com/hematology-oncology/article/190755/cythemias/inhibitor-can-improve-symptoms-systemic-mastocytosis?channel=50517
Jen Smith

Dec 8th, 2018 - Photo by Jen Smith Jason R. Gotlib, MD SAN DIEGO—The KIT D816V inhibitor avapritinib can improve symptoms of systemic mastocytosis (SM), according to researchers.

A Case of Systemic Mastocytosis With Associated Clonal Hematological Non-Mast Cell Lineage Disease at VA Pittsburgh Healthcare System
https://www.mdedge.com/fedprac/avaho/article/174895/lymphoma-plasma-cell-disorders/case-systemic-mastocytosis-associated
Liman AD, Gandhi A et. al.

Sep 14th, 2018 - Introduction: Systemic mastocytosis (SM) is a rare myeloid neoplasm that is caused by accumulation of abnormal mast cells in the bone marrow, liver, spleen, and skin. The KIT D816V mutation encodes a constitutively activated receptor tyrosine kina.

Avapritinib produces durable responses in SM
https://www.mdedge.com/hematology-oncology/article/184888/leukemia-myelodysplasia-transplantation/avapritinib-produces-durable
HT Staff

Jun 25th, 2018 - Photo from EHA Poster session at the 23rd Congress of the European Hematology Association (EHA) STOCKHOLM—The KIT/PDGFRA inhibitor avapritinib has produced durable responses in patients with systemic mastocytosis (SM). In the phase 1 EXPLORER tria.

Avapritinib yields high response rate in patients with systemic mastocytosis
https://www.mdedge.com/hematology-oncology/article/153966/myelodysplastic-syndrome/avapritinib-yields-high-response-rate
Andrew D. Bowser

Dec 10th, 2017 - ATLANTA – An oral investigational drug with specific activity against a mutation frequently found in advanced systemic mastocytosis (ASM) produced clinical responses in the majority treated patients, according to preliminary data presented at the.

see more →

Patient Education  5 results see all →